Back

Diabetes mellitus, time in the therapeutic range and adverse outcomes in patients with atrial fibrillation: insights from the AFFIRM study

18 March 2019 (15:35 - 16:25)
Organised by:
Congress Presentation Part of: Moderated ePosters 11: AF: stroke and anticoagulation Epidemiology, Prognosis, Outcome EHRA Premium Access EHRA 2019

About the speaker

Photo
Associate Professor Marco Proietti

University of Milan, Milan (Italy)

5 More presentations in this session

Presentation thumbnail
Different obesity paradox of ischemic stroke without and with atrial fibrillation
Assistant Professor Y. Baek (Incheon, KR)
Abstract
Presentation thumbnail
Usefulness of CHADS2-VASc score in predicting stroke in patients with atrial fibrillation and heart failure with preserved ejection fraction
Doctor A. Berkovitch (Ramat Gan, IL)
Abstract Slides
Presentation thumbnail
Thromboembolic events associated with cardioversion of atrial fibrillation in patients randomized to antiplatelet treatment in the ACTIVE trials
Doctor W. McIntyre (Hamilton, CA)
Abstract Slides
Presentation thumbnail
Prediction of Thromboembolic Events in Anticoagulated Patients with Atrial Fibrillation: Comparison of CHA2DS2-VASc and GARFIELD-AF Stroke Risk Scores
Doctor M. Proietti (Milan, IT)
Abstract Slides
Presentation thumbnail
Thromboembolism after electrical isolation of the left atrial appendage: a new indication for interventional closure
Doctor S. Bordignon (Frankfurt, DE)
Abstract Slides

Access the full session

Session thumbnail
Moderated ePosters 11: AF: stroke and anticoagulation

The Event

Event poster

EHRA 2019

18 March 2019 15:35 CET

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources